DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

27.49B

Market cap27.49B

Price-Earnings ratio

30.47

Price-Earnings ratio30.47

Dividend yield

—

Dividend yield—

Average volume

5.17M

Average volume5.17M

High today

$71.57

High today$71.57

Low today

$69.02

Low today$69.02

Open price

$69.17

Open price$69.17

Volume

3.17M

Volume3.17M

52 Week high

$89.98

52 Week high$89.98

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

With a market cap of 27.49B, DexCom(DXCM) trades at $71.25. The stock has a price-to-earnings ratio of 30.47.

On 2026-07-03, DexCom(DXCM) stock traded between a low of $69.02 and a high of $71.57. Shares are currently priced at $71.25, which is +3.2% above the low and -0.4% below the high.

DexCom(DXCM) shares are trading with a volume of 3.17M, against a daily average of 5.17M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $89.98 at its peak.

DXCM News

MarketWatch 14h

DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

...

Simply Wall St 3d

Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's Investment Narrative?

DexCom recently received FDA clearance to expand use of its Stelo Glucose Biosensor to children aged 2 and older who do not use insulin, and it is preparing to...

Simply Wall St 4d

Is DexCom A Bargain On FDA Cleared Stelo Expansion?

Advertisement FDA clearance for Stelo expansion puts DexCom (DXCM) back in focus DexCom (DXCM) is back on investors’ radar after the FDA cleared expanded use...

Analyst ratings

84%

of 31 ratings

Buy

83.9%

Hold

16.1%

Sell

More DXCM News

Simply Wall St 6d

DexCom Launches New Stelo App As It Expands Into Four Countries

DexCom is rolling out a redesigned Stelo app in July that aims to provide more accessible and actionable glucose insights to users. The company is preparing to...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.